WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY), a biopharmaceutical company, today announced the launch of the Incyte Charitable Giving Foundation, which will provide charitable donations to publicly-funded 501(c)(3) tax-exempt nonprofit organizations serving the needs of communities in Delaware.
The Foundation will focus its philanthropy on two areas—Oncology Patient Support and Resources and Community Partnerships. Organizations who offer services or resources to patients with cancer and their families in Delaware—helping them cope with their disease or condition—may apply to receive general operating or program support. Additionally, organizations dedicated to helping people in need in Delaware may apply to receive philanthropic and/or Incyte employee involvement and support.
“We are excited to launch the Foundation and contribute to the well-being of the communities we serve,” said Hervé Hoppenot, Incyte’s Chief Executive Officer. “Incyte was founded 15 years ago in Wilmington, Delaware and we are pleased to support organizations dedicated to creating positive change as well as those supporting patients with cancer and their families in our region.”
The Incyte Charitable Giving Foundation, chaired by Paula Swain, Incyte’s Executive Vice President, Human Resources, is part of Incyte Involved, the Company’s philanthropic and employee and community engagement program.
“Making a difference in the lives of patients and giving back to our local communities is an integral part of our culture and who we are as a company,” Swain said. “We are very pleased to expand Incyte Involved and grow our philanthropic, employee and community engagement programs through the Incyte Charitable Giving Foundation.”
For more information regarding Incyte Involved and the Incyte Charitable Giving Foundation, including the application process, funding guidelines, important information for applicants and quarterly submissions calendar, and please visit http://www.incyte.com/what-we-do/incyte-involved.aspx.
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company’s website at www.incyte.com.
Follow @Incyte on Twitter at https://twitter.com/Incyte.
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the expectations for, and the focus of, the Incyte Charitable Giving Foundation, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including, without limitation those risks detailed from time to time in the Incyte’s reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended March 31, 2016. Incyte disclaims any intent or obligation to update these forward-looking statements.